Homology modelling of the human adenosine A2B receptor based on X-ray structures of bovine rhodopsin, the β2-adrenergic receptor and the human adenosine A2A receptor

被引:0
作者
Farag F. Sherbiny
Anke C. Schiedel
Astrid Maaß
Christa E. Müller
机构
[1] Pharmaceutical Chemistry I,PharmaCenter Bonn, Pharmaceutical Institute
[2] Fraunhofer Institute SCAI,undefined
[3] Schloss Birlinghoven,undefined
来源
Journal of Computer-Aided Molecular Design | 2009年 / 23卷
关键词
Homology modelling; Adenosine A; receptor; Docking; Antagonist; Agonist;
D O I
暂无
中图分类号
学科分类号
摘要
A three-dimensional model of the human adenosine A2B receptor was generated by means of homology modelling, using the crystal structures of bovine rhodopsin, the β2-adrenergic receptor, and the human adenosine A2A receptor as templates. In order to compare the three resulting models, the binding modes of the adenosine A2B receptor antagonists theophylline, ZM241385, MRS1706, and PSB601 were investigated. The A2A-based model was much better able to stabilize the ligands in the binding site than the other models reflecting the high degree of similarity between A2A and A2B receptors: while the A2B receptor shares about 21% of the residues with rhodopsin, and 31% with the β2-adrenergic receptor, it is 56% identical to the adenosine A2A receptor. The A2A-based model was used for further studies. The model included the transmembrane domains, the extracellular and the intracellular hydrophilic loops as well as the terminal domains. In order to validate the usefulness of this model, a docking analysis of several selective and nonselective agonists and antagonists was carried out including a study of binding affinities and selectivities of these ligands with respect to the adenosine A2A and A2B receptors. A common binding site is proposed for antagonists and agonists based on homology modelling combined with site-directed mutagenesis and a comparison between experimental and calculated affinity data. The new, validated A2B receptor model may serve as a basis for developing more potent and selective drugs.
引用
收藏
页码:807 / 828
页数:21
相关论文
共 50 条
  • [21] Adenosine A2A Receptor as a Drug Target for Treatment of Sepsis
    Sivak, K. V.
    Vasin, A. V.
    Egorov, V. V.
    Tsevtkov, V. B.
    Kuzmich, N. N.
    Savina, V. A.
    Kiselev, O. I.
    MOLECULAR BIOLOGY, 2016, 50 (02) : 200 - 212
  • [22] The discovery and synthesis of novel adenosine receptor (A2A) antagonists
    Matasi, JJ
    Caldwell, JP
    Hao, JS
    Neustadt, B
    Arik, L
    Foster, CJ
    Lachowicz, J
    Tulshian, DB
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2005, 15 (05) : 1333 - 1336
  • [23] Adenosine A2A receptor agonists with potent antiplatelet activity
    Fuentes, Eduardo
    Fuentes, Manuel
    Caballero, Julio
    Palomo, Ivan
    Hinz, Sonja
    El-Tayeb, Ali
    Mueller, Christa E.
    PLATELETS, 2018, 29 (03) : 292 - 300
  • [24] In silico development of adenosine A2B receptor antagonists for sickle cell disease
    Rocha da Silva, Anna Carolina
    Carneiro Araujo, Janay Stefany
    da Rocha Pita, Samuel Silva
    Andrade Leite, Franco Henrique
    JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS, 2022, 40 (20) : 9592 - 9601
  • [25] Comparison of the Human A2A Adenosine Receptor Recognition by Adenosine and Inosine: New Insight from Supervised Molecular Dynamics Simulations
    Deganutti, Giuseppe
    Welihinda, Ajith
    Moro, Stefano
    CHEMMEDCHEM, 2017, 12 (16) : 1319 - 1326
  • [26] Progress in the discovery of selective, high affinity A2B adenosine receptor antagonists as clinical candidates
    Rao V. Kalla
    Jeff Zablocki
    Purinergic Signalling, 2009, 5 : 21 - 29
  • [27] Adenosine A2A receptor activation supports an atheroprotective cholesterol balance in human macrophages and endothelial cells
    Voloshyna, Iryna
    Carsons, Steven
    Littlefield, Michael J.
    Rieger, Jayson M.
    Figler, Robert
    Reiss, Allison B.
    BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS, 2013, 1831 (02): : 407 - 416
  • [28] Production of an agonist-like monoclonal antibody to the human A2A receptor of adenosine for clinical use
    By, Youlet
    Durand-Gorde, Josee-Martine
    Condo, Jocelyne
    Lejeune, Pierre-Jean
    Mallet, Bernard
    Carayon, Pierre
    Guieu, Regis
    Ruf, Jean
    MOLECULAR IMMUNOLOGY, 2009, 46 (03) : 400 - 405
  • [29] Inhibitory effects of benzodiazepines on the adenosine A2B receptor mediated secretion of interleukin-8 in human mast cells
    Hoffmann, Kristina
    Xifro, Rosa Altarcheh
    Hartweg, Julia Lisa
    Spitzlei, Petra
    Meis, Kirsten
    Molderings, Gerhard J.
    von Kuegelgen, Ivar
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2013, 700 (1-3) : 152 - 158
  • [30] Suppression of inflammatory and immune responses by the A2A adenosine receptor:: an introduction
    Palmer, T. M.
    Trevethick, M. A.
    BRITISH JOURNAL OF PHARMACOLOGY, 2008, 153 : S27 - S34